Podcast
MSL Talk: Tom Caravela, Mike Penkethman
How and Why Medical Affairs Can Support Diversity in Clinical Trials
Summary
In this episode, Tom Caravela is joined by Brad Atkinson, Brian Wilson, and Christina Wright to explore the critical role of diversity in clinical trials and the MSL’s part in fostering inclusivity. The discussion covers FDA guidance on diversity, challenges in therapeutic areas, and the importance of patient-centric approaches. The speakers delve into the strategic roles of MSLs in education and the historical context of diversity in clinical trials. They provide actionable strategies for field medical teams to enhance trial diversity and emphasize the significance of cultural awareness and allyship. The episode concludes with reflections and a call to action for promoting diversity in medical settings.
Christina Wright, Brad Atkinson and Brian Wilson discuss the important role Medical Affairs/MSLs can play in supporting diversity in clinical trials
The group discusses…
👉 Why does medical affairs need to be involved in diversity clinical trial initiatives?
👉 How can field medical get comfortable with the D and I conversation?
👉 What resources can be helpful
👉 3 Pillars of “Allyship”
👉 Why insights are currency
diversity in clinical trials, role of MSLs, FDA guidance on diversity, patient-centric approaches, cultural awareness and allyship
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Mike Penkethman
Podcast
MSL Talk: Tom Caravela, Josh Corriveau
MSL Career Options: The transition from Field Medical to Medical Director
Article
Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Article
Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
P.S. Mishra-Kalyani, L. Amiri Kordestani, D.R. Rivera, H. Singh, A. Ibrahim, R.A. DeClaro, Y. Shen, S. Tang, R. Sridhara, P.G. Kluetz, J. Concato, R. Pazdur, J.A. Beaver